{
    "root": "2f35f38f-6a69-f95e-e063-6294a90a96fa",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ATORVASTATIN CALCIUM",
    "value": "20250228",
    "ingredients": [
        {
            "name": "CALCIUM ACETATE",
            "code": "Y882YXF34X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM CARBONATE",
            "code": "45P3261C7T"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE",
            "code": "YRZ789OWMI"
        }
    ],
    "indications": "atorvastatin calcium tablets indicated : reduce risk : myocardial infarction ( myocardial infarction ) , stroke , revascularization procedures , angina adults multiple risk factors coronary heart disease ( chd ) without clinically evident chd myocardial infarction stroke adults type 2 diabetes mellitus multiple risk factors chd without clinically evident chd non-fatal myocardial infarction , fatal non-fatal stroke , revascularization procedures , hospitalization congestive heart failure , angina adults clinically evident chd adjunct diet reduce low-density lipoprotein cholesterol ( ldl-c ) : adults primary hyperlipidemia . adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 10 years older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet treatment adults : primary dysbetalipoproteinemia hypertriglyceridemia",
    "contraindications": "take orally daily without food ( 2.1 ) . assess ldl-c clinically appropriate , early 4 weeks initiating atorvastatin calcium , adjust necessary ( 2.1 ) . adults ( 2.2 ) : recommended starting 10 20 mg daily ; range 10 mg 80 mg daily . patients requiring ldl-c reduction > 45 % may start 40 mg daily . pediatric patients aged 10 years age older hefh : recommended starting 10 mg daily ; range 10 20 mg daily ( 2.3 ) . pediatric patients aged 10 years age older hofh : recommended starting 10 20 mg daily ; range 10 80 mg daily ( 2.4 ) . full prescribing information atorvastatin calcium tablets modifications due ( 2.5 ) .",
    "warningsAndPrecautions": "atorvastatin calcium tablets , usp supplied white off-white , oval , biconvex film-coated tablets atorvastatin calcium containing 10 mg atorvastatin . 10 mg tablets atorvastatin calcium tablets , usp 10 mg , available oral white off-white , oval , biconvex film-coated tablets , engraved \u201c apo \u201d one side , \u201c a10 \u201d side . bottles 30 ( ndc 43063-474-30 ) bottles 90 ( ndc 43063-474-90 ) storage store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispense tight container [ usp ] .",
    "adverseReactions": "acute liver failure decompensated cirrhosis [ ( 5.3 ) ] hypersensitivity atorvastatin excipients atorvastatin calcium tablets . hypersensitivity , including anaphylaxis , angioneurotic edema , erythema multiforme , stevens-johnson syndrome , toxic epidermal necrolysis , reported [ ( 6.2 ) ] .",
    "indications_original": "Atorvastatin Calcium Tablets are indicated:\n                  \n                     To reduce the risk of:\n  \n   \n                           Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD\n                           MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD\n                           Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD\n                        \n                     \n                     As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n  \n   \n                           Adults with primary hyperlipidemia.\n                           Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                        \n                     \n                     As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the treatment of adults with:\n  \n   \n                           Primary dysbetalipoproteinemia\n                           Hypertriglyceridemia",
    "contraindications_original": "Take orally once daily with or without food ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium, and adjust dosage if necessary ( 2.1 ). Adults ( 2.2 ): Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. Patients requiring LDL-C reduction >45% may start at 40 mg once daily. Pediatric Patients Aged 10 Years of Age and Older with HeFH: Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). Pediatric Patients Aged 10 Years of Age and Older with HoFH: Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). See full prescribing information for atorvastatin calcium tablets dosage modifications due to drug interactions ( 2.5 ).",
    "warningsAndPrecautions_original": "Atorvastatin calcium tablets, USP are supplied as white to off-white, oval, biconvex film-coated tablets of atorvastatin calcium containing 10 mg atorvastatin.\n                  \n                     10 mg tablets\n                  \n                  Atorvastatin calcium tablets, USP 10 mg, are available for oral administration as white to off-white, oval, biconvex film-coated tablets, engraved \u201cAPO\u201d on one side, \u201cA10\u201d on the other side.\u00a0\n                  Bottles of 30 (NDC 43063-474-30)\n                  Bottles of 90 (NDC 43063-474-90)\n                  \n                     Storage \n   \n                     Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted from 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\u00a0\n\n \n                  Dispense in a tight container [see USP].",
    "adverseReactions_original": "Acute liver failure or decompensated cirrhosis\n  \n   [see Warnings and Precautions (\n                        5.3)]\n \n  \n                     Hypersensitivity to atorvastatin or any excipients in atorvastatin calcium tablets. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported\n  \n   [see Adverse Reactions (\n   \n    6.2)]\n  \n   ."
}